SLGL vs. HUGE, TCRT, THTX, ACXP, ORGS, VYNE, GDTC, SNSE, SPRB, and ALRN
Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include FSD Pharma (HUGE), Alaunos Therapeutics (TCRT), Theratechnologies (THTX), Acurx Pharmaceuticals (ACXP), Orgenesis (ORGS), VYNE Therapeutics (VYNE), CytoMed Therapeutics (GDTC), Sensei Biotherapeutics (SNSE), Spruce Biosciences (SPRB), and Aileron Therapeutics (ALRN). These companies are all part of the "pharmaceutical preparations" industry.
Sol-Gel Technologies (NASDAQ:SLGL) and FSD Pharma (NASDAQ:HUGE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.
FSD Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -1,331.01%. Sol-Gel Technologies' return on equity of -61.52% beat FSD Pharma's return on equity.
Sol-Gel Technologies received 147 more outperform votes than FSD Pharma when rated by MarketBeat users.
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 1.2% of FSD Pharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 8.5% of FSD Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
FSD Pharma has lower revenue, but higher earnings than Sol-Gel Technologies. FSD Pharma is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, FSD Pharma had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 4 mentions for FSD Pharma and 3 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.96 beat FSD Pharma's score of 0.69 indicating that Sol-Gel Technologies is being referred to more favorably in the media.
Sol-Gel Technologies currently has a consensus price target of $8.00, suggesting a potential upside of 692.08%. Given Sol-Gel Technologies' higher probable upside, research analysts plainly believe Sol-Gel Technologies is more favorable than FSD Pharma.
Sol-Gel Technologies has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Summary
Sol-Gel Technologies beats FSD Pharma on 12 of the 16 factors compared between the two stocks.
Get Sol-Gel Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sol-Gel Technologies Competitors List
Related Companies and Tools